Menomune A / C / Y / W-135 Side Effects
Generic Name: meningococcal polysaccharide vaccine
Note: This document contains side effect information about meningococcal polysaccharide vaccine. Some of the dosage forms listed on this page may not apply to the brand name Menomune A / C / Y / W-135.
For the Consumer
Applies to meningococcal polysaccharide vaccine: parenteral for injection for sub-q use, parenteral solution for im use
Side effects include:
MenACWY-CRM (Menveo®): Injection site reactions (tenderness, erythema), irritability, sleepiness, persistent crying, change in eating habits, vomiting, diarrhea in infants 2 through 23 months of age; injection site reactions (pain, erythema, induration), irritability, sleepiness, malaise, headache in children 2 through 10 years of age; injection site pain, headache, myalgia, malaise, nausea in adults and adolescents.
MPSV4 (Menomune®): Injection site reactions (e.g., pain, erythema, induration, swelling), headache, malaise, chills, fever.
Hib-MenCY (MenHibrix®): Injection site reactions (e.g., pain, redness, swelling), systemic effects (e.g., fever, irritability, drowsiness, loss of appetite).
For Healthcare Professionals
Applies to meningococcal polysaccharide vaccine: subcutaneous powder for injection
The most common adverse events were injection site pain, headache, irritability, and diarrhea.[Ref]
Very common (10% or more): Injection site pain (48.1%), injection site redness (16%), injection site induration (11%), injection site tenderness
Common (1% to 10%): Injection site swelling, injection site hematoma
Uncommon (0.1% to 1%): Injection site reaction
Rare (less than 0.1%): Severe local reactions
Postmarketing reports: Extensive limb swelling at the injection site (frequently associated with erythema, sometimes involving the adjacent joint or swelling of the entire injected limb)[Ref]
Very common (10% or more): Headache (41.8%), drowsiness (11.2%)
Uncommon (0.1% to 1%): Hypoesthesia, dizziness
Very rare (less than 0.01%): Somnolence, neurological reactions
Very common (10% or more): Fatigue (32.3%), malaise (22.3%), fever
Common (1% to 10%): Chills, febrile reactions (>38C)
Very common (10% or more): Irritability (12.2%)
Very common (10% or more): Arthralgia (16%)
Uncommon (0.1% to 1%): Myalgia, pain in extremity
Postmarketing reports: Musculoskeletal stiffness[Ref]
Very common (10% or more): Appetite lost
Common (1% to 10%): Anorexia
Postmarketing reports: Decreased appetite[Ref]
Very common (10% or more): Diarrhea (14%)
Common (1% to 10%): Vomiting, nausea[Ref]
Common (1% to 10%): Rash
Uncommon (0.1% to 1%): Pruritus
Uncommon (0.1% to 1%): Upper respiratory tract illness
Rare (less than 0.1%): Wheeze[Ref]
1. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
2. Cerner Multum, Inc. "Australian Product Information." O 0
3. "Product Information. Menomune (meningococcal polysaccharide vaccine)." Sanofi Pasteur, Toronto, IA.
Some side effects may not be reported. You may report them to the FDA.
More about Menomune A/C/Y/W-135 (meningococcal polysaccharide vaccine)
- During Pregnancy
- Dosage Information
- Drug Interactions
- Pricing & Coupons
- En Español
- Drug class: bacterial vaccines